Indian drugmaker Biocon (BSE: 532523) has announced that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and prefilled syringe presentations, 2 mg/0.05 mL.
This approval paves the way for the launch of Yesafili in Canada, scheduled for next week. Yesafili is the first biosimilar to Eylea - a multi-indication ophthalmology drug marketed by Regeneron (Nasdaq: REGN) and Bayer (BAYN: DE) - to be approved by Health Canada.
Our 10th biosimilar to be commercialized worldwide
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze